Pharmacokinetics, Mass Balance, Safety, and Tolerability of Obeldesivir in Healthy ParticipantsOlena Anoshchenko, Rita Humeniuk, Heng Chen et al.|Clinical Pharmacology & Therapeutics|2024Cited by 12
THU-144-Ledipasvir/sofosbuvir for 8, 12, or 24 weeks is safe and effective in patients undergoing dialysisWan‐Long Chuang, Alessandra Mangia, Tsung‐Hui Hu et al.|Journal of Hepatology|2019Cited by 7